综述:血液系统恶性肿瘤中抗体类治疗相关药物性肝损伤
本综述探讨血液系统恶性肿瘤中单克隆抗体、抗体药物偶联物及T细胞重定向抗体所致药物性肝损伤(DILI),涉及机制、危险因素与管理策略。DILI表现从轻度转氨酶升高至严重肝损伤,危险因素包括既存肝病、遗传易感性及治疗特异性机制。当前管理包括常规肝功能监测、剂量调整及重症停药,但标准化指南仍缺乏,需进一步研究。
要点
- 抗体类治疗相关DILI可表现为轻度转氨酶升高至严重肝损伤。
- 危险因素包括既存肝病、遗传易感性和治疗特异性机制。
- 管理策略包括常规肝功能监测、剂量调整和重症停药,但标准化指南仍缺乏。
核心结论
- DILI仍是血液系统恶性肿瘤中抗体类治疗的主要挑战,需进一步研究以优化患者管理并平衡疗效与肝毒性风险。
研究设计与样本
- 本文为综述,全面回顾了血液系统恶性肿瘤背景下由抗体类治疗(包括单克隆抗体、抗体药物偶联物和T细胞重定向抗体)所致DILI的文献。
主要发现
- 抗体类治疗相关DILI的严重程度从轻度转氨酶升高到严重肝损伤不等。
- 危险因素包括既存肝病、遗传易感性以及免疫介导的肝损伤或直接肝毒性等治疗特异性机制。
- 当前管理策略包括常规肝功能监测、剂量调整以及在严重病例中停药。
临床怎么用
- 当前管理策略包括常规肝功能监测、剂量调整以及在严重病例中停药,但标准化指南仍缺乏。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Drug-induced liver injury (DILI) is a leading cause of liver damage. It is especially prevalent in haematologic malignancies, complicating treatment regimens and posing a risk for severe outcomes such as acute liver failure. Antibody-based therapies have significantly improved treatment outcomes. However, these therapies are increasingly associated with liver injury, posing challenges in clinical management. AIMS: This review aims to examine the DILI associated with antibody-based therapies in haematologic malignancies, highlighting key mechanisms, risk factors, clinical management strategies, and identifying areas that require further research. METHODS: We conducted a comprehensive review of the literature on DILI induced by antibody-based therapies, including monoclonal antibodies, antibody-drug conjugates, and T-cell redirecting antibodies, specifically in the context of haematologic malignancies. RESULTS: DILI associated with antibody-based therapies varies from mild transaminase elevations to severe liver injury. Risk factors include pre-existing liver disease, genetic predisposition, and therapy-specific mechanisms such as immune-mediated liver damage or direct hepatotoxic effects. Current management strategies involve routine liver function monitoring, dose modifications, and therapy discontinuation in severe cases. However, standardised guidelines remain lacking. CONCLUSIONS: DILI remains a major challenge in the use of antibody-based therapies for haematologic malignancies. While progress has been made in understanding risk factors and management strategies, further research is essential to optimise patient care and balance therapeutic efficacy with liver toxicity risks.
引用
- Lin M, Xie Y, Wu J, et al. Review Article: Drug-Induced Liver Injury Associated With Antibody-Based Therapies in Haematologic Malignancies. Aliment Pharmacol Ther. 2025. PMID: 40566645. doi:10.1111/apt.70228
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。